Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead vs Gilead: Indian court restrains 'infringer'

This article was originally published in Scrip

Executive Summary

This one for sure would have left Gilead Sciences stunned. The US firm, which sought to register a subsidiary by the name of Gilead Sciences Private Ltd in India earlier this year, has found to its dismay that such a company already exists in the country.

You may also be interested in...



Sun Wards Off Volini Infringers, Makes It Count Too

Sun Pharma has blocked a group of firms attempting to ride on the trademark of its popular pain relief brand Volini –  among the key products at the core of the Indian firm’s OTC business.

Sun Wards Off Volini Infringers, Makes It Count Too

Sun Pharma has blocked a group of firms attempting to ride on the trademark of its popular pain relief brand Volini –  among the key products at the core of the Indian firm’s OTC business.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel